Vir doses first subject in Phase II hepatitis D virus treatment trial

Vir doses first subject in Phase II hepatitis D virus treatment trial

Submitted by admin on September 23, 2022 - 10:32am
Source: 
Clinical Trials Arena
News Tags: 
Vir Biotechnology
hepatitis D
VIR-2218
VIR-3434
clinical trials
Headline: 
Vir doses first subject in Phase II hepatitis D virus treatment trial
snippet: 

Vir Biotechnology has dosed the first subject in the Phase II SOLSTICE clinical trial of VIR-2218 and VIR-3434 as monotherapy and together to treat patients with chronic hepatitis D virus (HDV) infection.

Do Not Allow Advertisers to Use My Personal information